The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance
Open accessAbstract
Although human cancers have complex genotypes and are genomically unstable, they often remain dependent on the continued presence of single-driver mutations—a phenomenon dubbed “oncogene addiction.” Such dependencies have been demonstrated in mouse models, where conditional expression systems have revealed that oncogenes able to initiate cancer are often required for tumor maintenance and progression, thus validating the pathways they control as therapeutic targets. Here, we implement an integrative approach that combines genetically defined mouse models, transcriptional profiling, and a novel inducible RNAi platform to characterize cellular programs that underlie addiction to MLL-AF9—a fusion oncoprotein involved in aggressive forms of acute myeloid leukemia (AML). We show that MLL-AF9 contributes to leukemia maintenance by enforcing a Myb-coordinated program of aberrant self-renewal involving genes linked to leukemia stem cell potential and poor prognosis in human AML. Accordingly, partial and transient Myb suppression precisely phenocopies MLL-AF9 withdrawal and eradicates aggressive AML in vivo without preventing normal myelopoiesis, indicating that strategies to inhibit Myb-dependent aberrant self-renewal programs hold promise as effective and cancer-specific therapeutics. Together, our results identify Myb as a critical mediator of oncogene addiction in AML, delineate relevant Myb target genes that are amenable to pharmacologic inhibition, and establish a general approach for dissecting oncogene addiction in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 3×
“…to the up-regulation of a selfrenewal-associated transcriptional subprogram in ‘‘leukemia stem cells’’ (LSCs) that is similar to embryonic stem cells (Krivtsov et al. 2006; Somervaille et al. 2009) and overlaps with a transcriptional program controlled by the Myc oncoprotein (Kim et al. 2010).”
BackgroundEstey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Control of the Embryonic Stem Cell State
Young, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.01.032 · Cited by 1,197
A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis
Mucenski, M. L., McLain, K., Kier, A. B., Swerdlow, S. H., Schreiner, C. M., Miller, T. A., Pietryga, D. W., Scott, W. J., & Potter, S. S. (1991) · Cell · doi:10.1016/0092-8674(91)90099-k · Cited by 1,042
Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,023
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
hDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804
Persson, M., Andrén, Y., Mark, J., Horlings, H. M., Persson, F., & Stenman, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909114106 · Cited by 788
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Kim, J., Woo, A. J., Chu, J., Snow, J. W., Fujiwara, Y., Kim, C. G., Cantor, A. B., & Orkin, S. H. (2010) · Cell · doi:10.1016/j.cell.2010.09.010 · Cited by 669
Cozzio, A., Passegué, E., Ayton, P. M., Karsunky, H., Cleary, M. L., & Weissman, I. L. (2003) · Genes & Development · doi:10.1101/gad.1143403 · Cited by 663
Repression of p53 activity by Smyd2-mediated methylation
Huang, J., Perez-Burgos, L., Placek, B. J., Sengupta, R., Richter, M., Dorsey, J. A., Kubicek, S., Opravil, S., Jenuwein, T., & Berger, S. L. (2006) · Nature · doi:10.1038/nature05287 · Cited by 624
MYB function in normal and cancer cells
Ramsay, R. G., & Gonda, T. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2439 · Cited by 617
Nanog and transcriptional networks in embryonic stem cell pluripotency
Pan, G., & Thomson, J. A. (2007) · Cell Research · doi:10.1038/sj.cr.7310125 · Cited by 611
Transcription factors in myeloid development: balancing differentiation with transformation
Rosenbauer, F., & Tenen, D. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2024 · Cited by 606 · cited 1×
“To identify genes that might mediate these effects, we focused our subsequent analysis on differentially expressed transcription factors, as these molecules govern cell fate in normal hematopoiesis (Rosenbauer and Tenen 2007).”
BackgroundLin, C., Smith, E. R., Takahashi, H., Lai, K. C., Martin-Brown, S., Florens, L., Washburn, M. P., Conaway, J. W., Conaway, R. C., & Shilatifard, A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.026 · Cited by 573
Steger, D. J., Lefterova, M. I., Ying, L., Stonestrom, A. J., Schupp, M., Zhuo, D., Vakoc, A. L., Kim, J.-E., Chen, J., Lazar, M. A., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02076-07 · Cited by 497
Self-citationPoliti, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478 · cited 2×
“…engineered to conditionally express particular oncogenes, where it was observed that withdrawal of oncogene expression could produce dramatic and complete tumor regressions, albeit with eventual disease relapse (Chin et al. 1999; Felsher and Bishop 1999; Gunther et al. 2003; Politi et al. 2006).”
BackgroundPlaisier, S. B., Taschereau, R., Wong, J. A., & Graeber, T. G. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq636 · Cited by 468
Self-citationTransformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9
Ayton, P. M., & Cleary, M. L. (2003) · Genes & Development · doi:10.1101/gad.1111603 · Cited by 436
Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., & Cleary, M. L. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.040 · Cited by 374
Metzeler, K. H., Hummel, M., Bloomfield, C. D., Spiekermann, K., Braess, J., Sauerland, M.-C., Heinecke, A., Radmacher, M., Marcucci, G., Whitman, S. P., et al. (2008) · Blood · doi:10.1182/blood-2008-02-134411 · Cited by 363
Somervaille, T. C. P., Matheny, C. J., Spencer, G. J., Iwasaki, M., Rinn, J. L., Witten, D. M., Chang, H. Y., Shurtleff, S. A., Downing, J. R., & Cleary, M. L. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.11.015 · Cited by 357
Schoch, C., Schnittger, S., Klaus, M., Kern, W., Hiddemann, W., & Haferlach, T. (2003) · Blood · doi:10.1182/blood-2003-02-0434 · Cited by 352
Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization
Zeisig, B. B., Milne, T., García-Cuéllar, M.-P., Schreiner, S., Martin, M.-E., Fuchs, U., Borkhardt, A., Chanda, S. K., Walker, J., Soden, R., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.617-628.2004 · Cited by 328
Milyavsky, M., Gan, O. I., Trottier, M., Komosa, M., Tabach, O., Notta, F., Lechman, E., Hermans, K. G., Eppert, K., Konovalova, Z., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.05.016 · Cited by 287
Clappier, E., Cuccuini, W., Kalota, A., Crinquette, A., Cayuela, J.-M., Dik, W. A., Langerak, A. W., Montpellier, B., Nadel, B., Walrafen, P., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064683 · Cited by 280
Mouse models of human AML accurately predict chemotherapy response
Zuber, J., Radtke, I., Pardee, T. S., Zhao, Z., Rappaport, A. R., Luo, W., McCurrach, M. E., Yang, M.-M., Dolan, M. E., Kogan, S. C., et al. (2009) · Genes & Development · doi:10.1101/gad.1771409 · Cited by 279
Self-citationMimicking the BH3 domain to kill cancer cells
Chonghaile, T. N., & Letai, A. (2008) · Oncogene · doi:10.1038/onc.2009.52 · Cited by 268
Zuber, J., McJunkin, K., Fellmann, C., Dow, L. E., Taylor, M. J., Hannon, G. J., & Lowe, S. W. (2011) · Nature Biotechnology · doi:10.1038/nbt.1720 · Cited by 267
Self-citationMeis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential
Wong, P., Iwasaki, M., Somervaille, T. C. P., So, C. W. E., & Cleary, M. L. (2007) · Genes & Development · doi:10.1101/gad.1602107 · Cited by 266
Definitive Hematopoiesis Requires the Mixed-Lineage Leukemia Gene
Ernst, P., Fisher, J. K., Avery, W., Wade, S., Foy, D., & Korsmeyer, S. J. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00061-9 · Cited by 265
Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb
Emambokus, N. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg434 · Cited by 259
Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemia
Hoelbl, A., Schuster, C., Kovacic, B., Zhu, B., Wickre, M., Hoelzl, M. A., Fajmann, S., Grebien, F., Warsch, W., Stengl, G., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000062 · Cited by 239
Methylation of the Retinoblastoma Tumor Suppressor by SMYD2
Saddic, L. A., West, L. E., Aslanian, A., Yates, J. R., Rubin, S. M., Gozani, O., & Sage, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137612 · Cited by 223
Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay
Fellmann, C., Zuber, J., McJunkin, K., Chang, K., Malone, C. D., Dickins, R. A., Xu, Q., Hengartner, M. O., Elledge, S. J., Hannon, G. J., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.008 · Cited by 222
Self-citationIsolation of human cDNA clones of myb-related genes, A-myb and B-myb
Nomura, N., Takahashi, M., Matsui, M., Ishii, S., Date, T., Sasamoto, S., & Ishizaki, R. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.23.11075 · Cited by 218
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis
Gunther, E. J., Moody, S. E., Belka, G. K., Hahn, K. T., Innocent, N., Dugan, K. D., Cardiff, R. D., & Chodosh, L. A. (2003) · Genes & Development · doi:10.1101/gad.1051603 · Cited by 214
Identification of a gene expression signature associated with pediatric AML prognosis
Yagi, T. (2003) · Blood · doi:10.1182/blood-2003-02-0578 · Cited by 209
Critical functions for c-Myb at three checkpoints during thymocyte development
Bender, T. P., Kremer, C. S., Kraus, M., Buch, T., & Rajewsky, K. (2004) · Nature Immunology · doi:10.1038/ni1085 · Cited by 192
Myc Represses Primitive Endoderm Differentiation in Pluripotent Stem Cells
Smith, K. N., Singh, A. M., & Dalton, S. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.023 · Cited by 188
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia
Radtke, I., Mullighan, C. G., Ishii, M., Su, X., Cheng, J., Ma, J., Ganti, R., Cai, Z., Goorha, S., Pounds, S. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903142106 · Cited by 177
Komatsu, S., Imoto, I., Tsuda, H., Kozaki, K.-I., Muramatsu, T., Shimada, Y., Aiko, S., Yoshizumi, Y., Ichikawa, D., Otsuji, E., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp116 · Cited by 173
The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors
Spannhoff, A., Hauser, A., Heinke, R., Sippl, W., & Jung, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200900301 · Cited by 171
c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells
Hess, J. L., Bittner, C. B., Zeisig, D. T., Bach, C., Fuchs, U., Borkhardt, A., Frampton, J., & Slany, R. K. (2006) · Blood · doi:10.1182/blood-2005-12-5014 · Cited by 166
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
Zhao, Z., Zuber, J., Diaz-Flores, E., Lintault, L., Kogan, S. C., Shannon, K., & Lowe, S. W. (2010) · Genes & Development · doi:10.1101/gad.1940710 · Cited by 166
Self-citationLieu, Y. K., & Reddy, E. P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907623106 · Cited by 163
Neubauer, A., Maharry, K., Mrózek, K., Thiede, C., Marcucci, G., Paschka, P., Mayer, R. J., Larson, R. A., Liu, E. T., & Bloomfield, C. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0418 · Cited by 158
Two Modes of c-myb Activation in Virus-Induced Mouse Myeloid Tumors
Shen-Ong, G. L. C., Morse, H. C., Potter, M., & Mushinski, J. F. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.2.380-392.1986 · Cited by 134
Ono, R., Nakajima, H., Ozaki, K., Kumagai, H., Kawashima, T., Taki, T., Kitamura, T., Hayashi, Y., & Nosaka, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22725 · Cited by 127
Jin, S., Zhao, H., Yi, Y., Nakata, Y., Kalota, A., & Gewirtz, A. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38030 · Cited by 123
Stubbs, M. C., Kim, Y., Krivtsov, A. V., Wright, R. D., Feng, Z., Agarwal, J., Kung, A. L., & Armstrong, S. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404951 · Cited by 117
c-Myb is required for progenitor cell homeostasis in colonic crypts
Malaterre, J., Carpinelli, M. R., Ernst, M., Alexander, W. S., Cooke, M. P., Sutton, S. E., Dworkin, S., Heath, J. K., Frampton, J., McArthur, G. A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610055104 · Cited by 113
Raf-1 Addiction in Ras-Induced Skin Carcinogenesis
Ehrenreiter, K., Kern, F., Velamoor, V., Meissl, K., Galabova‐Kovacs, G., Sibilia, M. C., & Baccarini, M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.008 · Cited by 106
Ratajczak, M. Z., Hijiya, N., Catani, L., DeRiel, K., Luger, S. M., McGlave, P. B., & Gewirtz, A. (1992) · Blood · doi:10.1182/blood.v79.8.1956.1956 · Cited by 105
Liang, D., Shih, L., Fu, J., Li, H., Wang, H., Hung, I., Yang, C., Jaing, T., Chen, S., & Liu, H. (2006) · Cancer · doi:10.1002/cncr.21687 · Cited by 101
Evans, J. L., Moore, T. L., Kuehl, W. M., Bender, T., & Ting, J. P. ‐. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5747 · Cited by 83
Luger, S. M., O’Brien, S. G., Ratajczak, J., Ratajczak, M. Z., Mick, R., Stadtmauer, E. A., Nowell̀, P. C., Goldman, J. M., & Gewirtz, A. M. (2002) · Blood · doi:10.1182/blood.v99.4.1150 · Cited by 79
The retinoblastoma gene is involved in multiple aspects of stem cell biology
Galderisi, U., Cipollaro, M., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209736 · Cited by 75
c-Myb Is Required for Pro-B Cell Differentiation
Fahl, S. P., Crittenden, R. B., Allman, D., & Bender, T. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901187 · Cited by 70
Reversible suppression of an essential gene in adult mice using transgenic RNA interference
McJunkin, K., Mazurek, A., Premsrirut, P. K., Zuber, J. A., Dow, L. E., Simon, J. M., Stillman, B., & Lowe, S. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104097108 · Cited by 50
Self-citationAcute Myeloid Leukemia With t(9;11)(p21–22;q23)
Chandra, P., Luthra, R., Zuo, Z., Yao, H., Ravandi, F., Reddy, N., Garcia‐Manero, G., Kantarjian, H. M., & Jones, D. M. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpgii1tt4nyogi · Cited by 36
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner
Pardee, T. S., Zuber, J. A., & Lowe, S. W. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.01.009 · Cited by 32
Self-citationKlempnauer, K.-H., & Bishop, J. M. (1984) · Journal of Virology · doi:10.1128/jvi.50.1.280-283.1984 · Cited by 16
Cited by
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Self-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Self-citationRNA N6-methyladenosine modification in cancers: current status and perspectives
Deng, X., Su, R., Weng, H., Huang, H., Li, Z., & Chen, J. (2018) · Cell Research · doi:10.1038/s41422-018-0034-6 · Cited by 845
An Optimized microRNA Backbone for Effective Single-Copy RNAi
Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M., Lai, D. Y., Barbosa, I. A. M., Kwon, J. S., Guan, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.020 · Cited by 719
Self-citation
Metadata
- Authors
- Zuber, J., Rappaport, A. R., Luo, W., Wang, E., Chen, C., Vaseva, A. V., Shi, J., Weissmueller, S., Fellman, C., Taylor, M. J., Weissenboeck, M., Graeber, T. G., Kogan, S. C., Vakoc, C. R., & Lowe, S. W.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-08-01
- Volume
- 25
- Issue
- 15
- Pages
- 1628-1640
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2122958542
- Cited by
- 279
- References
- 73
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.